Factors associated with refractoriness or early progression after idecabtagene vicleucel in patients with relapsed/ refractory multiple myeloma: US Myeloma Immunotherapy Consortium real world experience.

Haematologica · 2024 · PMC11063864 · PMID 37855036

Europe PMC DOI

hedged sentence

0.0400

closest p · 0.8× alpha

0.0400

boldest claim

The sentences

did not reach statistical significanceP =0.04actually significant

While this difference, and the presence of t(14;16) and deletion (17p), did not reach statistical significance, a higher number of patients in the early progression cohort had t(4:14) (21% vs. 8.9 %; P =0.04).

also in 39,124 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.